Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data Base

Conclusions: This is the largest study to evaluate the determinants of systemic therapy use in stage IV pancreatic cancer. The use of systemic therapy was significantly lower in patients older than 40 years, lower educational status, nonprivate insurance and with higher Charlson Comorbidity Scores. In addition, the use of systemic therapy was lower with female sex, African Americans/Hispanic, and lower socio-economic status. Understanding the barriers in the use of systemic therapy as well as appropriate utilization of systemic therapy can both optimize cancer care.
Source: Therapeutic Advances in Medical Oncology - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research